BriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS™ Immunotherapy for Cancer
August 16 2023 - 8:36AM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)
(“BriaCell” or the “Company”), a clinical-stage biotechnology
company that develops novel immunotherapies to transform cancer
care, is pleased to announce that the National Cancer Institute
(NCI), the United States federal government's principal agency for
cancer research and training, has awarded the Company a research
grant to advance its platform of personalized off-the-shelf
immunotherapies for cancer.
The grant award of non-dilutive funds is titled
“An off-the-shelf tumor cell vaccine with HLA-matching alleles for
the personalized treatment of advanced solid tumors”. The Company
intends to use the funds for the development of Bria-OTS™,
BriaCell’s novel personalized off-the-shelf immunotherapies for
advanced metastatic breast cancer, prostate cancer, lung cancer,
and melanoma.
“There is an urgent need for breakthrough cancer
treatments that would improve both survival and quality of life of
cancer patients, especially in those with advanced disease. Our
clinical findings to date show promising top-line survival and
quality of life outcomes in patients treated with our personalized
immunotherapy,” stated Dr. William V. Williams, BriaCell’s
President and CEO. “We would like to thank NCI for its generous
support, recognizing the urgency for this unmet medical need, and
considering our novel technology, among numerous other applicants,
as a treatment that could potentially revolutionize cancer care.
The NCI award further validates our approach and may facilitate
future non-dilutive funding opportunities.”
“Historically, the manufacturing and
administration of personalized cancer treatments have been very
time-consuming, complicated, and costly,” stated Dr. Miguel
Lopez-Lago, BriaCell’s Chief Scientific Officer. “Our cutting-edge
off-the-shelf personalized immunotherapies have the potential to
address all these issues and may represent a major advancement in
cancer care.”
About BriaCell Therapeutics
Corp.
BriaCell is a clinical-stage biotechnology
company that develops novel immunotherapies to transform cancer
care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” “will,” “would,” or the negative of
these words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements, including in relation to (i) intends to use the funds
for the development of Bria-OTS™; (ii) the results of any research
and development of Bria-OTS™; (iii) ability to obtain future
non-dilutive funding; and (iv) the ability to address issues
relating to manufacturing and administration of personalized cancer
treatments, are based on BriaCell’s current expectations and are
subject to inherent uncertainties, risks, and assumptions that are
difficult to predict. Further, certain forward-looking statements
are based on assumptions as to future events that may not prove to
be accurate. These and other risks and uncertainties are described
more fully under the heading “Risks and Uncertainties” in the
Company's most recent Management’s Discussion and Analysis, under
the heading "Risk Factors" in the Company's most recent Annual
Information Form, and under “Risks and Uncertainties” in the
Company's other filings with the Canadian securities regulatory
authorities and the U.S. Securities and Exchange Commission, all of
which are available under the Company's profiles on SEDAR at
www.sedar.com and on EDGAR at
www.sec.gov. Forward-looking statements contained
in this announcement are made as of this date, and BriaCell
Therapeutics Corp. undertakes no duty to update such information
except as required under applicable law.
Neither the Toronto Stock Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Toronto Stock Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Contact Information
Company Contact:William V.
Williams, MDPresident &
CEO1-888-485-6340info@briacell.com
Media Relations:Jules
AbrahamDirector of Public RelationsCORE
IR917-885-7378julesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
BriaCell Therapeutics (NASDAQ:BCTXW)
Historical Stock Chart
From Aug 2024 to Sep 2024
BriaCell Therapeutics (NASDAQ:BCTXW)
Historical Stock Chart
From Sep 2023 to Sep 2024